SCHEMBL155342

SCHEMBL155342

O=C(CCSSc1ccccn1)NCCCCNC(=O)CCSSc1ccccn1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 2/20 0.57
ALDH1A1 P00352 4/20 0.49
SMN1; SMN2 Q16637 4/20 0.45
NPC1 O15118 3/20 0.45
RAB9A P51151 3/20 0.45
HDAC3 O15379 2/20 0.44
HDAC4 P56524 2/20 0.44
HDAC1 Q13547 2/20 0.44
HDAC7 Q8WUI4 2/20 0.44
HDAC2 Q92769 2/20 0.44
HDAC10 Q969S8 2/20 0.44
HDAC11 Q96DB2 2/20 0.44
HDAC8 Q9BY41 2/20 0.44
HDAC6 Q9UBN7 2/20 0.44
HDAC9 Q9UKV0 2/20 0.44
HDAC5 Q9UQL6 2/20 0.44
EHMT2 Q96KQ7 1/20 0.43
EHMT1 Q9H9B1 1/20 0.43
APOBEC3G Q9HC16 1/20 0.43
KMT2A Q03164 3/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29380577 1.00 HPGD (0.57) HPGDALDH1A1SMN1; SMN2NPC1RAB9A
SCHEMBL19444563 0.99 HPGD (0.56) HPGDALDH1A1SMN1; SMN2NPC1RAB9A
SCHEMBL29276715 0.94 HPGD (0.55) HPGDALDH1A1SMN1; SMN2HDAC3HDAC4
SCHEMBL20648152 0.94 HPGD (0.52) HPGDALDH1A1SMN1; SMN2NPC1RAB9A
SCHEMBL15298801 0.94 HPGD (0.52) HPGDALDH1A1SMN1; SMN2NPC1RAB9A
SCHEMBL14341782 0.94 HPGD (0.52) HPGDALDH1A1SMN1; SMN2NPC1RAB9A
SCHEMBL10310074 0.94 HPGD (0.61) HPGDALDH1A1SMN1; SMN2NPC1RAB9A
SCHEMBL725097 0.94 HPGD (0.55) HPGDALDH1A1SMN1; SMN2HDAC3HDAC4
SCHEMBL16298865 0.93 HPGD (0.54) HPGDALDH1A1SMN1; SMN2NPC1RAB9A
SCHEMBL29276718 0.93 HPGD (0.57) HPGDALDH1A1SMN1; SMN2NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 334 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12472267-B2 Compositions containing nucleic acid nanoparticles with modular functionality Sixfold Bioscience Ltd. (GB) 2025-11-18 US claimed
EP-4594520-A2 COMPOSITIONS CONTAINING OLIGONUCLEOTIDES WITH THERANOSTIC APPLICATIONS Sixfold Bioscience Ltd. (GB) 2025-08-06 EP claimed
WO-2024069235-A2 COMPOSITIONS CONTAINING OLIGONUCLEOTIDES WITH THERANOSTIC APPLICATIONS Sixfold Bioscience Ltd. (GB) 2024-04-04 WO claimed
US-11725222-B2 Cleavable nucleotide analogs and uses thereof PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2023-08-15 US claimed
CN-115997016-A Composition comprising nucleic acid nanoparticles having modular functional groups 西克斯福德生物科学有限公司 2023-04-21 CN claimed
EP-4143316-A2 COMPOSITIONS CONTAINING NUCLEIC ACID NANOPARTICLES WITH MODULAR FUNCTIONALITY Sixfold Bioscience Ltd. (GB) 2023-03-08 EP claimed
US-20220370635-A1 COMPOSITIONS CONTAINING NUCLEIC ACID NANOPARTICLES WITH MODULAR FUNCTIONALITY SIXFOLD BIOSCIENCE LTD (GB) 2022-11-24 US claimed
US-11357865-B2 Compositions containing nucleic acid nanoparticles with modular functionality Sixfold Bioscience Ltd. (GB) 2022-06-14 US claimed
WO-2021220053-A2 COMPOSITIONS CONTAINING NUCLEIC ACID NANOPARTICLES WITH MODULAR FUNCTIONALITY Sixfold Bioscience Ltd. (GB) 2021-11-04 WO claimed
US-20210330810-A1 COMPOSITIONS CONTAINING NUCLEIC ACID NANOPARTICLES WITH MODULAR FUNCTIONALITY Sixfold Bioscience Ltd. (GB) 2021-10-28 US claimed
US-20190134177-A1 CONJUGATE FOR VACCINATION AGAINST TYPHOID COMPRISING CHEMICAL CONJUGATE OF VI POLYSACCHARIDE AND FLAGELLIN, A PROCESS FOR PRODUCING THE SAME AND A COMPOSITION COMPRISING THE CONJUGATE NAT INSTITUTE OF IMMUNOLOGY (IN) 2019-05-09 US claimed
WO-2018232180-A1 DEVICES AND METHODS FOR DELIVERING THERAPEUTICS SEMMA THERAPEUTICS, INC. (US) 2018-12-20 WO claimed
WO-2018102554-A1 CLEAVABLE NUCLEOTIDE ANALOGS AND USES THEREOF PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2018-06-07 WO claimed
EP-2494075-B1 TEMPLATED NANOCONJUGATES UNIV NORTHWESTERN (US) 2018-04-04 EP claimed
EP-2140270-A1 METHOD OF MASS SPECTROMETRY Micromass UK Limited (GB) 2010-01-06 EP claimed
EP-2073011-A1 Means and methods of processing biological samples Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) 2009-06-24 EP claimed
WO-2008125821-A1 METHOD OF MASS SPECTROMETRY MICROMASS UK LIMITED (GB) 2008-10-23 WO claimed
US-20060127310-A1 Amplification of biotin-mediated targeting ACCESS PHARMACEUTICALS AUSTRALIA PTY LTD. 2006-06-15 US claimed
EP-0701448-B1 AMPLIFICATION OF THE VITAMIN B 12 UPTAKE SYSTEM USING POLYMERS BIOTECH AUSTRALIA PTY LTD (AU) 2002-08-14 EP claimed
US-5449720-A Amplification of the VB12 uptake system using polymers BIOTECH AUSTRALIA PTY LIMITED (AU) 1995-09-12 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11357865-B2 Compositions containing nucleic acid nanoparticles with modular functionality NCL, NSUN3, POLN HPGD 4360/4885ALDH1A1 2270/4885SMN1; SMN2 657/4885
US-20220370635-A1 COMPOSITIONS CONTAINING NUCLEIC ACID NANOPARTICLES WITH MODULAR FUNCTIONALITY NCL, NSUN3, POLN HPGD 4360/4885ALDH1A1 2270/4885SMN1; SMN2 657/4885
US-20060127310-A1 Amplification of biotin-mediated targeting BTD, HLCS, SLC1A5 HPGD 3332/4885ALDH1A1 1010/4885SMN1; SMN2 4527/4885
US-20190134177-A1 CONJUGATE FOR VACCINATION AGAINST TYPHOID COMPRISING CHEMICAL CONJUGATE OF VI POLYSACCHARIDE AND FLAGELLIN, A PROCESS FOR PRODUCING THE SAME AND A COMPOSITION COMPRISING THE CONJUGATE TLR6, TLR5, TLR9 HPGD 2725/4885ALDH1A1 3784/4885SMN1; SMN2 3843/4885
US-20210330810-A1 COMPOSITIONS CONTAINING NUCLEIC ACID NANOPARTICLES WITH MODULAR FUNCTIONALITY NCL, NSUN3, POLN HPGD 4360/4885ALDH1A1 2270/4885SMN1; SMN2 657/4885
US-11725222-B2 Cleavable nucleotide analogs and uses thereof TYMP, DUT, NT5C3B HPGD 432/4885ALDH1A1 3387/4885SMN1; SMN2 2082/4885
US-12472267-B2 Compositions containing nucleic acid nanoparticles with modular functionality NCL, NSUN3, POLN HPGD 4360/4885ALDH1A1 2270/4885SMN1; SMN2 657/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.